Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world single-arm study of thiopifegrastin injection (HHPG-19K) for prevention of chemotherapy-induced neutropenia
ChiCTR2000039289Phase 4Recruiting
- Sponsor
- Quanzhou First Hospital
- Start
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mecapegfilgrastim in chemotherapy-induced neutropenia (CIN), sponsored by Quanzhou First Hospital. Primary endpoint: Adverse events. Started Oct 2020; status: recruiting.
02
Drugs
mecapegfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on ChiCTR2000039289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039289.